Affordable Access

deepdyve-link
Publisher Website

A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.

Authors
  • León-Cachón, Rafael B R1, 2
  • Ascacio-Martínez, Jorge A2
  • Gamino-Peña, María E3
  • Cerda-Flores, Ricardo M4
  • Meester, Irene1
  • Gallardo-Blanco, Hugo L5
  • Gómez-Silva, Magdalena3
  • Piñeyro-Garza, Everardo3
  • Barrera-Saldaña, Hugo A6, 7
  • Hugo Leonid Gallardo Blanco
Type
Published Article
Journal
BMC Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Feb 08, 2016
Volume
16
Pages
74–74
Identifiers
DOI: 10.1186/s12885-016-2062-2
PMID: 26857559
Source
Medline
License
Unknown

Abstract

Australian New Zealand Clinical Trials Registry: ACTRN12614000851662, date registered: August 8, 2014.

Report this publication

Statistics

Seen <100 times